Cattolico, C., Bailey, P. and Barry, S. T. (2022) Modulation of type I interferon responses to influence tumor-immune cross talk in PDAC. Frontiers in Cell and Developmental Biology, 10, 816517. (doi: 10.3389/fcell.2022.816517) (PMID:35273962) (PMCID:PMC8902310)
Text
266690.pdf - Published Version Available under License Creative Commons Attribution. 1MB |
Abstract
Immunotherapy has revolutionized the treatment of many cancer types. However, pancreatic ductal adenocarcinomas (PDACs) exhibit poor responses to immune checkpoint inhibitors with immunotherapy-based trials not generating convincing clinical activity. PDAC tumors often have low infiltration of tumor CD8+ T cells and a highly immunosuppressive microenvironment. These features classify PDAC as immunologically “cold.” However, the presence of tumor T cells is a favorable prognostic feature in PDAC. Intrinsic tumor cell properties govern interactions with the immune system. Alterations in tumor DNA such as genomic instability, high tumor mutation burden, and/or defects in DNA damage repair are associated with responses to both immunotherapy and chemotherapy. Cytotoxic or metabolic stress produced by radiation and/or chemotherapy can act as potent immune triggers and prime immune responses. Damage- or stress-mediated activation of nucleic acid-sensing pathways triggers type I interferon (IFN-I) responses that activate innate immune cells and natural killer cells, promote maturation of dendritic cells, and stimulate adaptive immunity. While PDAC exhibits intrinsic features that have the potential to engage immune cells, particularly following chemotherapy, these immune-sensing mechanisms are ineffective. Understanding where defects in innate immune triggers render the PDAC tumor–immune interface less effective, or how T-cell function is suppressed will help develop more effective treatments and harness the immune system for durable outcomes. This review will focus on the pivotal role played by IFN-I in promoting tumor cell–immune cell cross talk in PDAC. We will discuss how PDAC tumor cells bypass IFN-I signaling pathways and explore how these pathways can be co-opted or re-engaged to enhance the therapeutic outcome.
Item Type: | Articles |
---|---|
Additional Information: | This review was supported with financial grants by PRECODE (EU grant number: 861196). |
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Bailey, Dr Peter |
Authors: | Cattolico, C., Bailey, P., and Barry, S. T. |
College/School: | College of Medical Veterinary and Life Sciences > School of Cancer Sciences |
Journal Name: | Frontiers in Cell and Developmental Biology |
Publisher: | Frontiers Media |
ISSN: | 2296-634X |
ISSN (Online): | 2296-634X |
Copyright Holders: | Copyright © 2022 Cattolico, Bailey and Barry |
First Published: | First published in Frontiers in Cell and Developmental Biology 10: 816517 |
Publisher Policy: | Reproduced under a Creative Commons License |
University Staff: Request a correction | Enlighten Editors: Update this record